Synonym
JNJ-26070109; JNJ 26070109; JNJ26070109.
IUPAC/Chemical Name
4-bromo-N-[(1R)-1-(2,4-difluorophenyl)ethyl]-2-(quinoxalin-5-ylsulfonylamino)benzamide
InChi Key
TZKCPFFVWLRNRZ-CYBMUJFWSA-N
InChi Code
InChI=1S/C23H17BrF2N4O3S/c1-13(16-8-6-15(25)12-18(16)26)29-23(31)17-7-5-14(24)11-20(17)30-34(32,33)21-4-2-3-19-22(21)28-10-9-27-19/h2-13,30H,1H3,(H,29,31)/t13-/m1/s1
SMILES Code
O=C(N[C@@H](C1=CC=C(F)C=C1F)C)C2=CC=C(Br)C=C2NS(=O)(C3=C4N=CC=NC4=CC=C3)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
547.37
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Barrett TD, Lagaud G, Wagaman P, Freedman JM, Yan W, Andries L, Rizzolio MC, Morton MF, Shankley NP. The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol. 2012 Jul;166(5):1684-93. doi: 10.1111/j.1476-5381.2012.01878.x. PubMed PMID: 22300007; PubMed Central PMCID: PMC3419911.
2: Morton MF, Barrett TD, Freedman J, Li L, Rizzolio MC, Prendergast CE, Wu X, Moreno V, Pyati J, Figueroa K, Cagnon L, Lagaud G, Ver Donck L, Ghoos E, Allison B, Rabinowitz MH, Shankley NP. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-ben zamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011 Jul;338(1):328-36. doi: 10.1124/jpet.110.178483. PubMed PMID: 21493750.
3: Kirkham K. American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 2. 21-25 March 2010, San Francisco, CA, USA. IDrugs. 2010 May;13(5):292-4. PubMed PMID: 20432181.
